Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox
SYDNEY, Oct 14, 2021 – (ACN Newswire) – Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in quarantine, has launched an investment program designed to keep the invention Australian owned – while rolling out treatment to the world.Prof Thomas Borody- Topelia announces US$25 mil Series A capital raise to fund manufacture and clinical trials of the COVID-19 Antiviral Triple Therapy (ATT).- Topelia has secured exclusive global patent rights to COVID-19 Antiviral Triple Therapy from Prof Thomas Borody.- Borody’s track record includes effective treatment for Peptic Ulcers &…
Read More
0
